SES AI

SES AI (NYSE: SES) at \~$0.80: Is a Rebound Possible?

Last updated: October 13, 2026

Disclaimer: This post is for informational and educational purposes only. It is not financial advice, investment advice, a recommendation to buy or sell any security, or an offer to buy or sell securities. Investing in stocks, especially small-cap and pre-profit companies, involves substantial risk of loss, including the potential loss of your entire investment. Past performance is not indicative of future results. Market data, financial figures, and company developments can change rapidly. Always conduct your own thorough research, review the latest SEC filings and company disclosures, and consult with a qualified financial advisor before making any investment decisions. The author and publisher assume no liability for any actions taken based on this content.

SES AI (NYSE: SES) recently traded around $0.80 after a roughly 74% decline over the past year from a 52-week high of $3.73 (52-week low near $0.49). With a market capitalization near $297 million, the stock sits deep in micro-cap territory. Investors asking whether a rebound is possible are looking at a high-risk, high-volatility situation driven by a strategic pivot, early revenue traction, and several clear overhangs.

View the live chart and technicals on TradingView: NYSE:SES on TradingView

The Business Shift

SES AI develops AI-enhanced lithium-metal and lithium-ion battery technologies. It has moved away from a pure electric-vehicle solid-state focus toward nearer-term commercial opportunities:

• Energy storage systems (ESS), primarily through the UZ Energy business, which currently drives most revenue.
• Drone and unmanned systems cells, produced at the company’s Chungju, South Korea facility. The line has been converted and scaled toward approximately one million cells per year of NDAA-compliant production, with recent ISO 9001:2015 quality certification.
• Molecular Universe, an AI materials-discovery platform offered as software/subscriptions and used to identify new materials.

Revenue has grown sharply from a very small base (roughly $2 million to $21 million in 2025). Management has reaffirmed 2026 guidance of $30–35 million. In Q2 2026 the company reported about $5.1 million in revenue (up year-over-year but down sequentially), with gross margin improving into the low-to-mid 20% range. It remains unprofitable, with trailing-twelve-month EPS around –$0.20.

The balance sheet is relatively strong for a company at this stage: roughly $163 million in cash and short-term investments as of June 30, 2026, low debt, and management commentary pointing to multi-year liquidity under a capital-light model.

What Could Support a Rebound

Several factors give the stock speculative upside potential:

• Continued ramp of drone cells and ESS revenue, where NDAA compliance and domestic/ally supply-chain preferences can matter for U.S. defense and commercial customers.
• Further progress monetizing Molecular Universe.
• Analyst consensus price targets that have clustered near $2.55 (implying large upside from current levels), alongside mixed Buy/Hold ratings and some recent positive estimate revisions.
• Short interest in the mid-teens percent of float (days-to-cover roughly 2–3 days), which can amplify moves on positive news or volume.
• The stock has already staged a sharp bounce off September lows near $0.50.

The next earnings report (expected in the early-November window) will be watched for confirmation that the second-half ramp is materializing.

Track price action, volume, and indicators here: TradingView – SES Chart

Significant Risks and Overhangs

The bear case is straightforward and material:

• NYSE continued listing standard. In July 2026 the company received a non-compliance notice because its average closing price fell below $1.00 for 30 consecutive trading days. It has a six-month cure period (extending into early 2027). Compliance can be regained by achieving a $1.00 close and 30-day average on the last trading day of a month, or via other remedies that may include a reverse stock split. The stock is currently close to but still below the threshold, so this remains a real overhang.
• Persistent losses and cash burn. While the cash balance provides runway, ongoing operating losses mean the company must continue executing on revenue growth.
• Execution risk. Converting capacity and pipeline into sustained, higher-margin revenue is not guaranteed. Absolute revenue figures remain modest relative to the current market capitalization (price-to-sales roughly in the low-to-mid teens on trailing sales).
• Classic micro-cap volatility, potential dilution from a reverse split or future capital raises, and the noise that often accompanies sharp declines (including lawsuits or investigations).

Intrinsic-value models that emphasize current losses frequently flag the shares as expensive on pure fundamentals, even while revenue growth is real.

Bottom Line

A rebound toward $1 and potentially higher is possible if drone and ESS ramps accelerate, Molecular Universe gains commercial traction, or upcoming results exceed expectations—especially given the short interest and proximity to the listing threshold. It is equally possible the stock remains range-bound or declines further if guidance slips or the listing issue is not resolved cleanly.

SES AI is a speculative early-stage technology story with genuine technological differentiation and early commercial progress, not a lower-risk recovery candidate. Any position should be sized accordingly and viewed as high-risk capital.

Open SES Chart on TradingView

Final reminder: This is not a recommendation to buy, sell, or hold SES or any other security. Markets can move for reasons unrelated to fundamentals, and small-cap stocks can be illiquid and highly volatile. Review the company’s latest quarterly reports, 10-K/10-Q filings, and investor presentations, and speak with a licensed financial professional before acting.